Blockchain Registration Transaction Record

NeuroThera Launches Phase IIb Trial for Tourette Syndrome at Yale

NeuroThera Labs begins Phase IIb trial of SCI-110 for Tourette Syndrome at Yale Child Study Center. Promising results from Phase IIa show 21% tic reduction.

This news matters because Tourette Syndrome affects millions worldwide, yet current treatments are often inadequate, especially for adults with severe symptoms. SCI-110, if successful, could provide a novel and safer therapeutic option, potentially improving the quality of life for patients who have limited choices. The initiation of a U.S. site at a prestigious institution like Yale underscores the progress and credibility of the research, bringing hope for a new treatment that could address a significant unmet medical need.